Trending...
- Gas Wolf® Officially Becomes a Registered Trademark - 339
- Tobu Railway Announces a Price Revision on the "NIKKO PASS All Area" and "NIKKO PASS World Heritage Area," from April 20, 2025
- SutheDermal.com Launches: Revolutionizing Comfort in Self-Injection Therapies
PHILADELPHIA, April 8, 2025 /PRNewswire/ -- A securities class action lawsuit has been filed against Transmedics Group, Inc. ("TransMedics" or the "Company") (NASDAQ: TMDX). The lawsuit has been filed on behalf of purchasers of TransMedics securities between February 28, 2023 and January 10, 2025, inclusive (the "Class Period").
CLICK HERE TO LEARN MORE ABOUT THIS LAWSUIT.
Investors who purchased or acquired Transmedics Group, Inc. securities during the Class Period may, no later than APRIL 15, 2025, seek to be appointed as a lead plaintiff representative of the class.
According to the lawsuit, throughout the Class Period, the Company and its senior executives misled investors and/or failed to disclose that: (1) TransMedics used kickbacks, fraudulent overbilling, and coercive tactics to generate business and revenue; (2) TransMedics concealed safety issues and a lack of safety oversight within the organization.
Investors learned the truth about TransMedics on February 21, 2024, when U.S. Rep. Paul Gosar sent a letter to the Company accusing it of, among other things, misappropriating corporate resources and gouging transplant centers. On this news, the price of TransMedics stock fell $2.18 per share, or 2.5%, to a close of $84.81 per share on February 22, 2024.
More on The PennZone
Then, on January 10, 2025, Scorpion Capital issued a report accusing TransMedics of, among other things, overbilling hospitals and providing patients with organs that had been rejected by reputable physicians. According to the action, on this news, TransMedics shares fell $3.74 per share, or 5%, to a closing price of $68.81 on January 10, 2025, and another $4.76 per share (6.9%) on January 13, 2025, to close at $64.05 per share.
For additional information or to learn how to participate in this litigation, please contact Berger Montague: Andrew Abramowitz at [email protected] or (215) 875-3015, or Peter Hamner at [email protected], or CLICK HERE.
A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation. The lead plaintiff is usually the investor or small group of investors who have the largest financial interest and who are also adequate and typical of the proposed class of investors. The lead plaintiff selects counsel to represent the lead plaintiff and the class and these attorneys, if approved by the court, are lead or class counsel. Your ability to share in any recovery is not, however, affected by the decision whether or not to serve as a lead plaintiff. Communicating with any counsel is not necessary to participate or share in any recovery achieved in this case. Any member of the purported class may move the Court to serve as a lead plaintiff through counsel of his/her choice, or may choose to do nothing and remain an inactive class member.
More on The PennZone
Berger Montague, with offices in Philadelphia, Minneapolis, Delaware, Washington, D.C., San Diego, San Francisco and Chicago, has been a pioneer in securities class action litigation since its founding in 1970. Berger Montague has represented individual and institutional investors for over five decades and serves as lead counsel in courts throughout the United States.
Contact:
Andrew Abramowitz, Senior Counsel
Berger Montague
(215) 875-3015
[email protected]
Peter Hamner
Berger Montague PC
[email protected]
SOURCE Berger Montague
CLICK HERE TO LEARN MORE ABOUT THIS LAWSUIT.
Investors who purchased or acquired Transmedics Group, Inc. securities during the Class Period may, no later than APRIL 15, 2025, seek to be appointed as a lead plaintiff representative of the class.
According to the lawsuit, throughout the Class Period, the Company and its senior executives misled investors and/or failed to disclose that: (1) TransMedics used kickbacks, fraudulent overbilling, and coercive tactics to generate business and revenue; (2) TransMedics concealed safety issues and a lack of safety oversight within the organization.
Investors learned the truth about TransMedics on February 21, 2024, when U.S. Rep. Paul Gosar sent a letter to the Company accusing it of, among other things, misappropriating corporate resources and gouging transplant centers. On this news, the price of TransMedics stock fell $2.18 per share, or 2.5%, to a close of $84.81 per share on February 22, 2024.
More on The PennZone
- Boston Industrial Solutions, Inc. Unveils Natron® 504N UV LED Inks Designed for EPSON Printheads
- Kavelle Christie: Trump's First 100 Days Mark Alarming Breakdown in Healthcare, Public Health, and Freedoms
- Good Deeds Plumbing & HVAC Revolutionizes Home Services with a Mission to Give Back
- OpenSSL Technical Advisory Committee Elections Now Open – Cast Your Vote
- Axiros Confirms Continued Compliance with ISO/IEC 27001:2022 After Surveillance Audit
Then, on January 10, 2025, Scorpion Capital issued a report accusing TransMedics of, among other things, overbilling hospitals and providing patients with organs that had been rejected by reputable physicians. According to the action, on this news, TransMedics shares fell $3.74 per share, or 5%, to a closing price of $68.81 on January 10, 2025, and another $4.76 per share (6.9%) on January 13, 2025, to close at $64.05 per share.
For additional information or to learn how to participate in this litigation, please contact Berger Montague: Andrew Abramowitz at [email protected] or (215) 875-3015, or Peter Hamner at [email protected], or CLICK HERE.
A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation. The lead plaintiff is usually the investor or small group of investors who have the largest financial interest and who are also adequate and typical of the proposed class of investors. The lead plaintiff selects counsel to represent the lead plaintiff and the class and these attorneys, if approved by the court, are lead or class counsel. Your ability to share in any recovery is not, however, affected by the decision whether or not to serve as a lead plaintiff. Communicating with any counsel is not necessary to participate or share in any recovery achieved in this case. Any member of the purported class may move the Court to serve as a lead plaintiff through counsel of his/her choice, or may choose to do nothing and remain an inactive class member.
More on The PennZone
- Twitter's Buzzing! What's the Deal with PhotoG, the AI Everyone's Talking About?
- New WHO Mental Health Guidelines Condemn Coercive Psychiatry
- Keenan's Caring Konnections, LLC
- Celebrate Children's Day in Tochigi City!
- Mensa identifies best board games of 2025
Berger Montague, with offices in Philadelphia, Minneapolis, Delaware, Washington, D.C., San Diego, San Francisco and Chicago, has been a pioneer in securities class action litigation since its founding in 1970. Berger Montague has represented individual and institutional investors for over five decades and serves as lead counsel in courts throughout the United States.
Contact:
Andrew Abramowitz, Senior Counsel
Berger Montague
(215) 875-3015
[email protected]
Peter Hamner
Berger Montague PC
[email protected]
SOURCE Berger Montague
Filed Under: Business
0 Comments
Latest on The PennZone
- Fairfield Inn by Marriott Scottsdale Old Town Opens
- Benchmark International Successfully Facilitated the Trans Between Spadone LLC and Private Investors
- Pelican Reef Group Announces Grand Opening of New High Point Showroom – IHFC Building H-621 & Event April 27th, 2025
- NaturismRE Launches the 11 Levels of Naturism: A Groundbreaking Framework Guiding the Global Naturist Journey
- K2 Integrity and Sonata One Partner to Accelerate Capital Raising, Reduce Risk, and Deliver Scalable Advisory Services for Private Fund Managers
- The World's No.1 Superstar™ Walks Where Legends Rest: A Sacred Encounter in Rome Before the Pope's Passing
- Coming Up on "Financial Freedom with Tom Hegna" Financial Expert Parker Faulkner
- Tobu Railway Announces a Price Revision on the "NIKKO PASS All Area" and "NIKKO PASS World Heritage Area," from April 20, 2025
- Kemeny, Ramp & Renaud, LLC Welcomes Prominent Trusts and Estates Attorney Gary B. Cornick to Its Firm
- Rocket Lab USA (NASDAQ: RKLB) Deadline Approaching: Berger Montague Advises Investors of Deadline in Securities Fraud Lawsuit
- Straightening Teeth in Reading: Exeter Smiles Keeps it Affordable
- SutheDermal.com Launches: Revolutionizing Comfort in Self-Injection Therapies
- Local Commitment, National Expansion
- S2C and Andes Technology Announce FPGA-Based Prototyping Partnership to Accelerate Advanced RISC-V SoC Development
- CCHR Florida to Host a Veteran Advocates Networking Event
- Students Celebrate Earth Month and Learn About the Lifecycle of Trees
- Pennsylvania Business Central Names Colleen Hanson to Annual Top 100 People List
- Electives Appoints DraftKings' CPO Linda Aiello to Board Amid Record Quarter
- Blue Ocean Business School's Deputy Dean Delivers Keynote Address at India Blockchain Summit
- AdvisorVault's Consolidated 17a-4 D3P Service® Full Feature Set Available